A citation-based method for searching scientific literature

Robert L Coleman, Katelyn F Handley, Robert Burger, Graziela Zibetti Dal Molin, Robert Stagg, Anil K Sood, Kathleen N Moore. Gynecol Oncol 2020
Times Cited: 9







List of co-cited articles
210 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.
Mark J McKeage, Dusan Kotasek, Ben Markman, Manuel Hidalgo, Michael J Millward, Michael B Jameson, Dean L Harris, Robert J Stagg, Ann M Kapoun, Lu Xu,[...]. Target Oncol 2018
25
55

A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.
Elena Gabriela Chiorean, Patricia LoRusso, Robert Matthew Strother, Jennifer R Diamond, Anne Younger, Wells A Messersmith, Lieve Adriaens, Liming Liu, Richard J Kao, Albert Thomas DiCioccio,[...]. Clin Cancer Res 2015
73
55

A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.
Antonio Jimeno, Kathleen N Moore, Michael Gordon, Rashmi Chugh, Jennifer R Diamond, Raid Aljumaily, David Mendelson, Ann M Kapoun, Lu Xu, Robert Stagg,[...]. Invest New Drugs 2019
25
55

Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia.
Jeremy B Samon, Mireia Castillo-Martin, Michael Hadler, Alberto Ambesi-Impiobato, Elisabeth Paietta, Janis Racevskis, Peter H Wiernik, Jacob M Rowe, John Jakubczak, Sophia Randolph,[...]. Mol Cancer Ther 2012
79
44

The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis.
Rui Benedito, Cristina Roca, Inga Sörensen, Susanne Adams, Achim Gossler, Marcus Fruttiger, Ralf H Adams. Cell 2009
652
44

Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.
Marzia A Locatelli, Philippe Aftimos, E Claire Dees, Patricia M LoRusso, Mark D Pegram, Ahmad Awada, Bo Huang, Rossano Cesari, Yuqiu Jiang, M Naveed Shaik,[...]. Oncotarget 2017
39
44

A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.
David C Smith, Rashmi Chugh, Amita Patnaik, Kyriakos P Papadopoulos, Min Wang, Ann M Kapoun, Lu Xu, Jakob Dupont, Robert J Stagg, Anthony Tolcher. Invest New Drugs 2019
26
44

Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity.
Bruno M Simões, Ciara S O'Brien, Rachel Eyre, Andreia Silva, Ling Yu, Aida Sarmiento-Castro, Denis G Alférez, Kath Spence, Angélica Santiago-Gómez, Francesca Chemi,[...]. Cell Rep 2015
104
44

The Varied Roles of Notch in Cancer.
Jon C Aster, Warren S Pear, Stephen C Blacklow. Annu Rev Pathol 2017
238
44

Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.
V Agnusdei, S Minuzzo, C Frasson, A Grassi, F Axelrod, S Satyal, A Gurney, T Hoey, E Seganfreddo, G Basso,[...]. Leukemia 2014
79
44

Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency.
Wan-Ching Yen, Marcus M Fischer, Fumiko Axelrod, Christopher Bond, Jennifer Cain, Belinda Cancilla, William R Henner, Rene Meisner, Aaron Sato, Jalpa Shah,[...]. Clin Cancer Res 2015
155
44

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer.
C Massard, A Azaro, J-C Soria, U Lassen, C Le Tourneau, D Sarker, C Smith, U Ohnmacht, G Oakley, B K R Patel,[...]. Ann Oncol 2018
53
44

A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors.
David C Smith, Peter D Eisenberg, Georgy Manikhas, Rashmi Chugh, Matthew A Gubens, Robert J Stagg, Ann M Kapoun, Lu Xu, Jakob Dupont, Branimir Sikic. Clin Cancer Res 2014
87
44

Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.
Jie Huang, Wei Hu, Limin Hu, Rebecca A Previs, Heather J Dalton, Xiao-Yun Yang, Yunjie Sun, Michael McGuire, Rajesha Rupaimoole, Archana S Nagaraja,[...]. Mol Cancer Ther 2016
23
44

Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.
Cathy C Zhang, Zhengming Yan, Qing Zong, Douglas D Fang, Cory Painter, Qin Zhang, Enhong Chen, Maruja E Lira, Annette John-Baptiste, James G Christensen. Stem Cells Transl Med 2013
62
33

Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
Frank Kuhnert, Guoying Chen, Sandra Coetzee, Nithya Thambi, Carlos Hickey, Jing Shan, Pavel Kovalenko, Irene Noguera-Troise, Eric Smith, Jeanette Fairhurst,[...]. Cancer Res 2015
23
33

DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.
Timothy Hoey, Wan-Ching Yen, Fumiko Axelrod, Jesspreet Basi, Lucas Donigian, Scott Dylla, Maureen Fitch-Bruhns, Sasha Lazetic, In-Kyung Park, Aaron Sato,[...]. Cell Stem Cell 2009
291
33

Notch3 and pre-TCR interaction unveils distinct NF-kappaB pathways in T-cell development and leukemia.
Alessandra Vacca, Maria Pia Felli, Rocco Palermo, Giuseppina Di Mario, Angelica Calce, Monica Di Giovine, Luigi Frati, Alberto Gulino, Isabella Screpanti. EMBO J 2006
113
33

Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia.
Tomas Vilimas, Joaquina Mascarenhas, Teresa Palomero, Malay Mandal, Silvia Buonamici, Fanyong Meng, Benjamín Thompson, Christina Spaulding, Sami Macaroun, Maria-Luisa Alegre,[...]. Nat Med 2007
247
33

Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.
Andrew P Weng, Adolfo A Ferrando, Woojoong Lee, John P Morris, Lewis B Silverman, Cheryll Sanchez-Irizarry, Stephen C Blacklow, A Thomas Look, Jon C Aster. Science 2004
33

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).
Suzanne Richter, Philippe L Bedard, Eric Xueyu Chen, Blaise A Clarke, Ben Tran, Sebastien J Hotte, Anastasios Stathis, Hal W Hirte, Albiruni R A Razak, Michael Reedijk,[...]. Invest New Drugs 2014
56
33

Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma.
Katherine M Morgan, Bruce S Fischer, Francis Y Lee, Jamie J Shah, Joseph R Bertino, Jeffrey Rosenfeld, Amartya Singh, Hossein Khiabanian, Sharon R Pine. Mol Cancer Ther 2017
27
33

A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.
R Ferrarotto, G Eckhardt, A Patnaik, P LoRusso, L Faoro, J V Heymach, A M Kapoun, L Xu, P Munster. Ann Oncol 2018
32
33

Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).
Shivaani Kummar, Geraldine O'Sullivan Coyne, Khanh T Do, Baris Turkbey, Paul S Meltzer, Eric Polley, Peter L Choyke, Robert Meehan, Rasa Vilimas, Yvonne Horneffer,[...]. J Clin Oncol 2017
71
33

Direct inhibition of the NOTCH transcription factor complex.
Raymond E Moellering, Melanie Cornejo, Tina N Davis, Cristina Del Bianco, Jon C Aster, Stephen C Blacklow, Andrew L Kung, D Gary Gilliland, Gregory L Verdine, James E Bradner. Nature 2009
552
33

A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
C Papayannidis, D J DeAngelo, W Stock, B Huang, M N Shaik, R Cesari, X Zheng, J M Reynolds, P A English, M Ozeck,[...]. Blood Cancer J 2015
67
33

Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy.
Shannon M McAuliffe, Stefanie L Morgan, Gregory A Wyant, Lieu T Tran, Katherine W Muto, Yu Sarah Chen, Kenneth T Chin, Justin C Partridge, Barish B Poole, Kuang-Hung Cheng,[...]. Proc Natl Acad Sci U S A 2012
222
33

Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation.
A Rangarajan, C Talora, R Okuyama, M Nicolas, C Mammucari, H Oh, J C Aster, S Krishna, D Metzger, P Chambon,[...]. EMBO J 2001
655
33

Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor.
Hannah Harrison, Gillian Farnie, Sacha J Howell, Rebecca E Rock, Spyros Stylianou, Keith R Brennan, Nigel J Bundred, Robert B Clarke. Cancer Res 2010
355
33

NOTCH3 expression is linked to breast cancer seeding and distant metastasis.
Alexey A Leontovich, Mohammad Jalalirad, Jeffrey L Salisbury, Lisa Mills, Candace Haddox, Mark Schroeder, Ann Tuma, Maria E Guicciardi, Luca Zammataro, Mario W Gambino,[...]. Breast Cancer Res 2018
32
33

A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014.
Wells A Messersmith, Geoffrey I Shapiro, James M Cleary, Antonio Jimeno, Arvind Dasari, Bo Huang, M Naveed Shaik, Rossano Cesari, Xianxian Zheng, Jennifer M Reynolds,[...]. Clin Cancer Res 2015
116
33

Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.
Pedro J Real, Valeria Tosello, Teresa Palomero, Mireia Castillo, Eva Hernando, Elisa de Stanchina, Maria Luisa Sulis, Kelly Barnes, Catherine Sawai, Irene Homminga,[...]. Nat Med 2009
314
33


EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling.
Rajeswara Rao Arasada, Joseph M Amann, Mohammad A Rahman, Stacey S Huppert, David P Carbone. Cancer Res 2014
79
33

Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival.
Andrew Baker, Debra Wyatt, Maurizio Bocchetta, Jun Li, Aleksandra Filipovic, Andrew Green, Daniel S Peiffer, Suzanne Fuqua, Lucio Miele, Kathy S Albain,[...]. Oncogene 2018
49
33

A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.
Zishuo Ian Hu, Johanna C Bendell, Andrea Bullock, Noelle K LoConte, Hassan Hatoum, Paul Ritch, Hugo Hool, Joseph W Leach, James Sanchez, Davendra P S Sohal,[...]. Cancer Med 2019
22
33

Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells.
L L Song, Y Peng, J Yun, P Rizzo, V Chaturvedi, S Weijzen, W M Kast, P J B Stone, L Santos, A Loredo,[...]. Oncogene 2008
97
33

Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial.
Ran Xu, Fumiko Shimizu, Koos Hovinga, Kathryn Beal, Sasan Karimi, Leif Droms, Kyung K Peck, Philip Gutin, J Bryan Iorgulescu, Thomas Kaley,[...]. Clin Cancer Res 2016
57
33

Alterations of the Notch pathway in lung cancer.
Britta Westhoff, Ivan N Colaluca, Giovanni D'Ario, Maddalena Donzelli, Daniela Tosoni, Sara Volorio, Giuseppe Pelosi, Lorenzo Spaggiari, Giovanni Mazzarol, Giuseppe Viale,[...]. Proc Natl Acad Sci U S A 2009
280
33

TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms.
L W Ellisen, J Bird, D C West, A L Soreng, T C Reynolds, S D Smith, J Sklar. Cell 1991
33

Therapeutic antibody targeting of individual Notch receptors.
Yan Wu, Carol Cain-Hom, Lisa Choy, Thijs J Hagenbeek, Gladys P de Leon, Yongmei Chen, David Finkle, Rayna Venook, Xiumin Wu, John Ridgway,[...]. Nature 2010
505
33

Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy.
Hanqiu Zheng, Yangjin Bae, Sabine Kasimir-Bauer, Rebecca Tang, Jin Chen, Guangwen Ren, Min Yuan, Mark Esposito, Wenyang Li, Yong Wei,[...]. Cancer Cell 2017
73
33

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
Laura R Saunders, Alexander J Bankovich, Wade C Anderson, Monette A Aujay, Sheila Bheddah, KristenAnn Black, Radhika Desai, Paul A Escarpe, Johannes Hampl, Amy Laysang,[...]. Sci Transl Med 2015
278
33

DLL3: an emerging target in small cell lung cancer.
Dwight H Owen, Michael J Giffin, Julie M Bailis, Marie-Anne Damiette Smit, David P Carbone, Kai He. J Hematol Oncol 2019
44
33

Chronic DLL4 blockade induces vascular neoplasms.
Minhong Yan, Christopher A Callahan, Joseph C Beyer, Krishna P Allamneni, Gu Zhang, John Brady Ridgway, Kyle Niessen, Greg D Plowman. Nature 2010
211
33

Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.
Anne F Schott, Melissa D Landis, Gabriela Dontu, Kent A Griffith, Rachel M Layman, Ian Krop, Lacey A Paskett, Helen Wong, Lacey E Dobrolecki, Michael T Lewis,[...]. Clin Cancer Res 2013
147
33

Novel TCR-Mediated Mechanisms of Notch Activation and Signaling.
Martin Peter Steinbuck, Ksenia Arakcheeva, Susan Winandy. J Immunol 2018
23
33

Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors.
Ian Krop, Tim Demuth, Tina Guthrie, Patrick Y Wen, Warren P Mason, Prakash Chinnaiyan, Nicholas Butowski, Morris D Groves, Santosh Kesari, Steven J Freedman,[...]. J Clin Oncol 2012
201
33

Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells.
Johan H van Es, Marielle E van Gijn, Orbicia Riccio, Maaike van den Born, Marc Vooijs, Harry Begthel, Miranda Cozijnsen, Sylvie Robine, Doug J Winton, Freddy Radtke,[...]. Nature 2005
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.